MYLAN GETS FINAL APPROVAL FOR GENERIC PLETAL

The FDA has granted Mylan Laboratories final approval to market its version of Otsuka Pharmaceutical's blood circulation drug Pletal.

Mylan will market the drug in 50- and 100-mg tablets and said it will begin shipping the product immediately.